Ongoing Adjuvant Trials with Trastuzumab in Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 54-64

  Tan, Antoinette R ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE NEU; ONCOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0242552468     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.008     Document Type: Conference Paper

References (30)

1. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
2. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
4. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
5. Carr JA, Havstad S, Zarbo RJ, et al: The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 135:1469-1474, 2000
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
8. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
9. Jahanzeb M, Mortimer J, Yunus J, et al: Weekly herceptin with navelbine in chemonaive patients with HER2 positive metastatic breast cancer: A phase II multicenter trial. Breast Cancer Res Treat 69:284, 2001 (abstr 429)
10. Burstein HJ, Marcom PK, Lambert-Falls R, et al: Multicenter phase II study of trastuzumab and vinorelbine as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+ MBC). Proc Am Soc Clin Oncol 21:53a, 2002 (abstr 211)
11. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
12. O'Shaughnessy J, Vukelja SJ, Marsland T, et al: Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: Preliminary results. Clin Breast Cancer 3:17-20, 2002 (suppl 1)
13. Sledge GW, O'Neill A, Thor AD, et al: Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198). Breast Cancer Res Treat 69:209, 2001 (abstr 4)
14. Gelmon K, Arnold A, Verma S, et al: Pharmacokinetics and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 20:69a, 2001 (abstr 271)
15. Mass RD, Press M, Anderson S, et al: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20:22a, 2001 (abstr 85)
16. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002
17. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002
18. National Surgical Adjuvant Breast and Bowel Project B-31. Available at: http://clinicaltrials.gov (accessed September 19, 2002)
19. Henderson IC, Berry D, Demetri G, et al: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390a)
20. Adjuvant Therapy for Breast Cancer: NIH Consensus Statement, November 1-3, 17:1-35, 2000. Available at: http://consensus.nih.gov
21. North Central Cancer Treatment Group N9831: Available at: http://clinicaltrials.gov (accessed September 19, 2002)
22. Breast Cancer International Research Group 006. Available at: http://clinicaltrials.gov (accessed September 19, 2002)
23. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
24. Konecny G, Pegram MD, Beryt M, et al: Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/NEU overexpression. Breast Cancer Res Treat 57:114, 1999 (abstr 467)
25. Nabholtz JM, Crown J, Yonemoto L, et al: Results of two open-label multicentre pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) as therapy for advanced breast cancer in women overexpressing HER2. Breast Cancer Res Treat 64:82, 2000 (abstr 327)
26. Trastuzumab (Herceptin) [package insert]. South San Francisco, CA, Genentech, Inc, 2002
27. Breast International Group 01-01. Available at: http://clinicaltrials. gov (accessed September 19, 2002)
28. Fédération Nationale des Centres de Lutte Contre le Cancer Programmes d'Actions Concertées 04. Available at: http://www.fnclcc.fr (accessed November 22, 2002)
29. Cancer and Leukemia Group B 49808. Available at: http://clinicaltrials.gov (accessed September 19, 2002)
30. Theodoulou M, Campos S, Welles L, et al: Cardiac safety and efficacy of TLC D99 (D, Myocet) and Herceptin in advanced breast cancer. Breast Cancer Res Treat 69:283, 2001 (abstr 427)